Rhythm Pharmaceuticals Inc. | Mid-cap | Healthcare

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 48.5M
Gross Profit 43.0M 88.57%
Operating Income -45.3M -93.39%
Net Income -46.6M -96.14%
EPS (Diluted) $-0.75

Balance Sheet Metrics

Total Assets 386.7M
Total Liabilities 223.6M
Shareholders Equity 163.1M
Debt to Equity 1.37

Cash Flow Metrics

Operating Cash Flow -35.4M
Free Cash Flow -40.4M

Revenue & Profitability Trend

Rhythm Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i130.1M77.4M23.6M3.2M0
Cost of Goods Sold i13.4M9.3M2.1M599.0K0
Gross Profit i116.8M68.1M21.5M2.6M0
Gross Margin % i89.7%88.0%91.0%81.0%0.0%
Operating Expenses
Research & Development i238.0M135.0M108.6M104.1M90.4M
Selling, General & Administrative i144.3M117.5M92.0M68.5M46.1M
Other Operating Expenses i-----
Total Operating Expenses i382.3M252.5M200.7M172.6M136.6M
Operating Income i-265.5M-184.4M-179.2M-170.1M-136.6M
Operating Margin % i-204.0%-238.1%-757.9%-5,391.9%0.0%
Non-Operating Items
Interest Income i14.7M13.9M4.0M447.0K2.6M
Interest Expense i20.6M13.9M5.2M00
Other Non-Operating Income11.1M190.0K-790.0K100.0M-
Pre-tax Income i-260.3M-184.1M-181.1M-69.6M-134.0M
Income Tax i346.0K564.0K00-
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-260.6M-184.7M-181.1M-69.6M-134.0M
Net Margin % i-200.3%-238.5%-766.2%-2,207.1%0.0%
Key Metrics
EBITDA i-247.0M-168.5M-174.2M-68.5M-133.3M
EPS (Basic) i$-4.34$-3.20$-3.47$-1.40$-3.04
EPS (Diluted) i$-4.34$-3.20$-3.47$-1.40$-3.04
Basic Shares Outstanding i6099520457673128521207014960029444127220
Diluted Shares Outstanding i6099520457673128521207014960029444127220

Income Statement Trend

Rhythm Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i89.1M60.1M127.7M59.2M100.9M
Short-term Investments i231.4M215.8M205.6M235.6M71.9M
Accounts Receivable i18.5M14.9M6.2M1.0M0
Inventory i18.7M8.6M2.9M111.0K-
Other Current Assets8.8M6.7M7.4M4.0M3.0M
Total Current Assets i374.2M308.3M354.2M308.4M181.7M
Non-Current Assets
Property, Plant & Equipment i3.5M781.0K1.2M1.5M1.8M
Goodwill i6.2M7.0M7.9M4.7M0
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets7.8M15.3M17.0M12.1M403.0K
Total Non-Current Assets i18.1M24.5M28.2M21.1M5.4M
Total Assets i392.3M332.7M382.5M329.5M187.1M
Liabilities
Current Liabilities
Accounts Payable i12.3M4.9M4.8M5.7M4.9M
Short-term Debt i-770.0K684.0K606.0K535.0K
Current Portion of Long-term Debt-----
Other Current Liabilities42.1M5.4M2.4M800.0K180.0K
Total Current Liabilities i115.5M55.2M39.8M43.4M18.0M
Non-Current Liabilities
Long-term Debt i3.9M490.0K1.3M1.9M2.6M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities-----
Total Non-Current Liabilities i112.2M107.8M78.4M1.9M2.6M
Total Liabilities i227.7M163.0M118.2M45.4M20.5M
Equity
Common Stock i61.0K59.0K56.0K50.0K44.0K
Retained Earnings i-1.2B-894.7M-710.1M-528.9M-459.3M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i164.5M169.8M264.3M284.2M166.5M
Key Metrics
Total Debt i3.9M1.3M1.9M2.6M3.1M
Working Capital i258.7M253.1M314.4M265.0M163.7M

Balance Sheet Composition

Rhythm Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-260.6M-184.7M-181.1M-69.6M-134.0M
Depreciation & Amortization i1.6M1.8M1.7M1.2M690.0K
Stock-Based Compensation i39.7M32.6M19.8M20.8M17.5M
Working Capital Changes i16.1M1.9M-17.9M5.2M-6.4M
Operating Cash Flow i-89.9M-129.0M-172.4M-42.7M-122.5M
Investing Activities
Capital Expenditures i0-47.0K-281.0K-434.0K-214.0K
Acquisitions i-00100.0M0
Investment Purchases i-268.3M-354.9M-251.9M-525.0M-86.9M
Investment Sales i260.6M355.0M284.2M361.2M245.6M
Investing Cash Flow i-48.2M-5.7M32.0M-64.2M158.5M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i-----
Debt Repayment i-----
Financing Cash Flow i174.0M65.8M203.4M161.7M0
Free Cash Flow i-113.9M-136.2M-177.7M-151.4M-122.2M
Net Change in Cash i36.0M-68.8M63.1M54.9M36.0M

Cash Flow Trend

Rhythm Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -22.82
Forward P/E -37.09
Price to Book 47.21
Price to Sales 42.08
PEG Ratio -0.63

Profitability Ratios

Profit Margin -117.16%
Operating Margin -93.39%
Return on Equity -116.97%
Return on Assets -29.39%

Financial Health

Current Ratio 2.79
Debt to Equity 85.33
Beta 2.12

Per Share Data

EPS (TTM) $-3.01
Book Value per Share $-0.19
Revenue per Share $2.51

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
rytm6.6B-22.8247.21-116.97%-117.16%85.33
Vertex 103.4B28.686.0222.77%31.86%8.89
Regeneron 63.8B15.132.0915.34%31.37%9.04
Madrigal 9.9B-20.2314.14-36.30%-54.68%17.81
Bio-Techne 9.8B136.855.083.68%6.02%23.14
Corcept Therapeutics 9.3B78.7114.6021.70%18.67%1.04

Financial data is updated regularly. All figures are in the company's reporting currency.